Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update

Open access
Cadinu, Daniela, Grayson, Ben, Podda, Giovanni, Harte, Michael K., Doostdar, Nazanin, Neill, Joanna C. · 2018 · Neuropharmacology

Abstract

&NA; Negative and cognitive deficit symptoms in schizophrenia remain an unmet clinical need. Improved understanding of the neuro‐ and psychopathology of cognitive dysfunction in the illness is urgently required to enhance the development of new improved therapeutic strategies. Careful validation of animal models that mimic the behaviour and pathology of complex psychiatric disorders is an essential step towards this goal. Non‐competitive NMDAR (N‐Methyl‐d‐aspartate receptor) antagonists e.g. phencyclidine (PCP), ketamine and dizocilpine (MK‐801) can effectively replicate certain aspects of negative and cognitive deficits associated with schizophrenia in animals. In 2010 we reviewed the effects of NMDAR antagonism in tests for domains of cognition affected in schizophrenia, social behaviour and neuropathology, and in 2014, in tests for negative symptoms. In this update, we evaluate the most recent pharmacological strategies for restoring cognition in schizophrenia using NMDAR antagonist models, published since our original review in 2010 (cited over 225 times, excluding self‐citations). Tests reviewed are, novel object recognition for visual recognition memory, attentional set shifting for executive function, and operant tests incorporating recent touchscreen technology for a range of domains including working memory, problem solving and attention, all impaired in schizophrenia. Moreover, we include an update on parvalbumin (PV)‐expressing GABAergic interneurons and review, for the first time, the effects of NMDAR antagonists on gamma oscillations, circuitry integral for effective cognition. Data summarized in this review strongly confirm the reliability and usefulness of NMDAR antagonist animal models for evaluating novel therapeutic candidates, and for improving our understanding of the pathophysiology of cognitive deficits in schizophrenia. This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’. HighlightsNMDAR antagonists impair cognition relevant for schizophrenia in rodent tests.New therapeutic targets for cognition are evaluated in these tests.Effects of NMDAR antagonists on neuropathology and gamma oscillations are reviewed.Evaluation of novel treatments on behaviour and pathophysiology is recommended.Evaluation of novel treatments in more than one animal model is recommended.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.11.045

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 168

Metadata

Authors
Cadinu, D., Grayson, B., Podda, G., Harte, M. K., Doostdar, N., & Neill, J. C.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2018-11
Volume
142
Pages
41-62
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2768536557
Cited by
168
References
33
FWCI
10.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.